Polatuzumab vedotin, an antibody-drug conjugate directed against CD79b, received U.S. FDA approval in June 2019 in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL after at least two prior therapies (61). This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.